Spots Global Cancer Trial Database for prostatic disease
Every month we try and update this database with for prostatic disease cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC) | NCT04249947 | Prostatic Neopl... Neoplasms by Hi... Neoplasms, Pros... Prostate Cancer Metastatic Cast... Neoplasms Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Prostatic Disea... Salivary Gland ... Salivary Gland ... Adenoid Cystic ... Salivary Duct C... Mucoepidermoid ... Acinic Cell Tum... | P-PSMA-101 CAR-... Rimiducid | 18 Years - | Poseida Therapeutics, Inc. | |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. | NCT01310894 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance. | NCT01310894 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy | NCT04461509 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Neoplasms by Si... Neoplasms Genital Disease... Prostatic Disea... | 18F-PSMA | 18 Years - | Cedars-Sinai Medical Center | |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | NCT05150236 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Prostate Cancer Neoplasms by Si... Neoplasms Prostatic Disea... | 177Lu-PSMA-617 Ipilimumab Nivolumab | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment | NCT00210249 | Lymphoma Digestive Syste... Ovarian Disease... Pulmonary Disea... Prostatic Disea... Bladder Disease | 70 Years - | Institut Bergonié | ||
| Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate Cancer | NCT04225299 | Localized Prost... | TOOKAD® | 18 Years - | Steba Biotech S.A. | |
| Study Using WST11 in Patients With Localized Prostate Cancer | NCT00975429 | Prostate Cancer | WST11 WST11 | 18 Years - | Steba Biotech S.A. | |
| Study of WST11 in Patients With Localized Prostate Cancer | NCT00707356 | Prostate Cancer | WST11 | 18 Years - | Steba Biotech S.A. | |
| Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer | NCT01875393 | Prostate Cancer | TOOKAD® Soluble | 18 Years - | Steba Biotech S.A. | |
| Micro-Ultrasound/Magnetic Resonance Imaging 001 | NCT03938376 | Diagnoses Disea... | Micro-Ultrasoun... | - | University Health Network, Toronto | |
| Study Using WST11 in Patients With Localized Prostate Cancer | NCT00975429 | Prostate Cancer | WST11 WST11 | 18 Years - | Steba Biotech S.A. | |
| Development of an Evaluation Method of Elderly Condition in Patient Receiving Chemotherapy Treatment | NCT00210249 | Lymphoma Digestive Syste... Ovarian Disease... Pulmonary Disea... Prostatic Disea... Bladder Disease | 70 Years - | Institut Bergonié | ||
| Study Using WST11 in Patients With Localized Prostate Cancer | NCT00975429 | Prostate Cancer | WST11 WST11 | 18 Years - | Steba Biotech S.A. | |
| Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | NCT06190899 | mCRPC (Metastat... Genital Disease... Urogenital Dise... Prostatic Disea... Prostatic Neopl... Prostate Cancer | Gedatolisib Darolutamide | 18 Years - | Celcuity Inc | |
| EVOLUTION: 177Lu-PSMA Therapy Versus 177Lu-PSMA in Combination With Ipilimumab and Nivolumab for Men With mCRPC | NCT05150236 | Prostatic Neopl... Genital Neoplas... Urogenital Neop... Prostate Cancer Neoplasms by Si... Neoplasms Prostatic Disea... | 177Lu-PSMA-617 Ipilimumab Nivolumab | 18 Years - | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | |
| Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer | NCT00946881 | Prostate Cancer | WST 11 -mediate... | 18 Years - | Steba Biotech S.A. | |
| Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer | NCT00946881 | Prostate Cancer | WST 11 -mediate... | 18 Years - | Steba Biotech S.A. | |
| A Study of FT-7051 in Men With MCRPC | NCT04575766 | Metastatic Cast... | FT-7051 | 18 Years - | Novo Nordisk A/S |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
